Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554

Global Prevalence of Diabetes

Sarah H. Wild, Gojka Roglić, Anders Green et al. · Diabetes Care · 2004 · 15.3K citations

Public Health, Demography, Population Health Sciences +12

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Timothy J. Kieffer, Christopher H.S. McIntosh, Raymond A. Pederson · Endocrinology · 1995 · 1.1K citations

Life Sciences, Biochemistry, Endocrinology +17

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Bo Åhrén, Mona Landin‐Olsson, Per‐Anders Jansson et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 713 citations

Medicine, Endocrinology, Pharmacology +17